Skip to Main content Skip to Navigation

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

Document type :
Conference papers
Complete list of metadatas

https://www.hal.inserm.fr/inserm-02413130
Contributor : Valerie Taly <>
Submitted on : Monday, December 16, 2019 - 9:58:07 AM
Last modification on : Friday, March 27, 2020 - 2:44:19 AM

Identifiers

  • HAL Id : inserm-02413130, version 1

Citation

Julien Taieb, Valérie Taly, Dewi Vernerey, Camille Bourreau, Jaafar Bennouna, et al.. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. 44th Congress of the European-Society-for-Medical-Oncology (ESMO) Location: Barcelona, SPAIN Date: SEP 27-OCT 01, 2019, Sep 2019, Barcelone, France. ⟨inserm-02413130⟩

Share

Metrics

Record views

51